264 related articles for article (PubMed ID: 16625853)
21. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly.
Serri O; Beauregard C; Hardy J
J Clin Endocrinol Metab; 2004 Feb; 89(2):658-61. PubMed ID: 14764777
[TBL] [Abstract][Full Text] [Related]
22. The critical parameters in GH excess.
Sheppard MC
J Endocrinol Invest; 2005; 28(5 Suppl):92-5. PubMed ID: 16114283
[TBL] [Abstract][Full Text] [Related]
23. Remission criteria for the follow-up of patients with acromegaly.
Gullu S; Keles H; Delibasi T; Tonyukuk V; Kamel N; Erdogan G
Eur J Endocrinol; 2004 Apr; 150(4):465-71. PubMed ID: 15080775
[TBL] [Abstract][Full Text] [Related]
24. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
Bastemir M; Akin F; Yaylali GF
Neuroendocrinology; 2007; 86(2):119-23. PubMed ID: 17671378
[TBL] [Abstract][Full Text] [Related]
25. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly.
Espinosa-de-los-Monteros AL; Mercado M; Sosa E; Lizama O; Guinto G; Lopez-Felix B; Garcia O; Hernández I; Ovalle A; Mendoza V
J Neurosurg; 2002 Aug; 97(2):287-92. PubMed ID: 12186455
[TBL] [Abstract][Full Text] [Related]
26. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly.
Biermasz NR; Pereira AM; Smit JW; Romijn JA; Roelfsema F
Growth Horm IGF Res; 2005 Jun; 15(3):200-6. PubMed ID: 15935982
[TBL] [Abstract][Full Text] [Related]
27. Gender and age in the biochemical assessment of cure of acromegaly.
Freda PU; Landman RE; Sundeen RE; Post KD
Pituitary; 2001 Aug; 4(3):163-71. PubMed ID: 12138989
[TBL] [Abstract][Full Text] [Related]
28. GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment.
Colao A; Terzolo M; Bondanelli M; Galderisi M; Vitale G; Reimondo G; Ambrosio MR; Pivonello R; Lombardi G; Angeli A; degli Uberti EC
Clin Endocrinol (Oxf); 2008 Oct; 69(4):613-20. PubMed ID: 18410555
[TBL] [Abstract][Full Text] [Related]
29. Two hour mean GH is not superior to basal GH for the follow-up of acromegalic patients treated with Octreotide LAR.
Taboada GF; Correa LL; de Oliveira Machado E; van Haute FR; Casini AF; Balarini GA; Neto LV; Calixto L; Calixto C; Gadelha MR
Growth Horm IGF Res; 2007 Feb; 17(1):77-81. PubMed ID: 17314058
[TBL] [Abstract][Full Text] [Related]
30. Clinical laboratory indices in the treatment of acromegaly.
Clemmons DR
Clin Chim Acta; 2011 Feb; 412(5-6):403-9. PubMed ID: 21075098
[TBL] [Abstract][Full Text] [Related]
31. Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly.
Sherlock M; Aragon Alonso A; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
Clin Endocrinol (Oxf); 2009 Jul; 71(1):74-81. PubMed ID: 19178529
[TBL] [Abstract][Full Text] [Related]
32. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels.
Freda PU; Nuruzzaman AT; Reyes CM; Sundeen RE; Post KD
J Clin Endocrinol Metab; 2004 Feb; 89(2):495-500. PubMed ID: 14764751
[TBL] [Abstract][Full Text] [Related]
33. Biochemical markers of acromegalic activity.
Jasper H; Chervin A; Vitale M; Mella A; Ropelato G; Basso A
Medicina (B Aires); 1994; 54(1):25-30. PubMed ID: 7990682
[TBL] [Abstract][Full Text] [Related]
34. Biochemical markers of acromegaly: GH vs. IGF-I.
Barkan AL
Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S97-100. PubMed ID: 15135787
[TBL] [Abstract][Full Text] [Related]
35. Measurement of basal growth hormone (GH) is a useful test of disease activity in treated acromegalic patients.
Jayasena CN; Wujanto C; Donaldson M; Todd JF; Meeran K
Clin Endocrinol (Oxf); 2008 Jan; 68(1):36-41. PubMed ID: 18088288
[TBL] [Abstract][Full Text] [Related]
36. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center.
Barrande G; Pittino-Lungo M; Coste J; Ponvert D; Bertagna X; Luton JP; Bertherat J
J Clin Endocrinol Metab; 2000 Oct; 85(10):3779-85. PubMed ID: 11061538
[TBL] [Abstract][Full Text] [Related]
37. Pregnancy-induced changes in insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-3), and acid-labile subunit (ALS) in patients with growth hormone (GH) deficiency and excess.
Wiesli P; Zwimpfer C; Zapf J; Schmid C
Acta Obstet Gynecol Scand; 2006; 85(8):900-5. PubMed ID: 16862465
[TBL] [Abstract][Full Text] [Related]
38. Dynamic testing in the diagnosis and follow-up of patients with acromegaly.
Wass JA
J Endocrinol Invest; 2003; 26(7 Suppl):48-53. PubMed ID: 14604066
[TBL] [Abstract][Full Text] [Related]
39. Use of the oral glucose tolerance test to define remission in acromegaly.
Vierhapper H; Heinze G; Gessl A; Exner M; Bieglmayr C
Metabolism; 2003 Feb; 52(2):181-5. PubMed ID: 12601629
[TBL] [Abstract][Full Text] [Related]
40. Serum IGF-I measured by four different immunoassays in patients with adult GH deficiency or acromegaly and in a control population.
Granada ML; Ulied A; Casanueva FF; Pico A; Lucas T; Torres E; Sanmartí A
Clin Endocrinol (Oxf); 2008 Jun; 68(6):942-50. PubMed ID: 17980002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
